NOT-EB-24-019: Notice of NIBIB Participation in RFA-NS-25-021: "BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)"

Notice of NIBIB Participation in RFA-NS-25-021: "BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)"

Notice Number:

NOT-EB-24-019

Key Dates

Release Date:

November 14, 2024

Related Announcements

November 5, 2024 - BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional). See NOFO RFA-NS-25-021.

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this Notice is to inform potential applicants that effective November 15, 2024, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) will participate in RFA-NS-25-021, "BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)", issued by the National Institutes of Health.

The following text has been added to reflect NIBIB’s participation in the NOFO:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.286

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Michael Wolfson
NIBIB/OPESP
Telephone: 301-451-4778
Email: Michael.Wolfson@nih.gov